A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease

计划入组 0 人

Treatment of Psychosis and Agitation in Alzheimer's Disease

计划入组 77 人 · 首次发布于 2014 年 5 月 2 日

ACP-204 in Adults With Alzheimer's Disease Psychosis

计划入组 1,074 人 · 首次发布于 2023 年 12 月 7 日

Alzheimer’s disease(AstronauTx)

T-5369186

Alzheimer's Disease And Related Disorders Association, Inc.

United States

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

United States

KarXT Approval Faces Scrutiny Over Potential Labeling Issues, Analyst Warns

Acadia Pharmaceuticals Eyes Billion-Dollar Sales Milestone and Global Expansion

MapLight Therapeutics Receives FDA Fast Track Designation for Alzheimer's Disease Psychosis Treatment